Nasal administration of the neuroprotective candidate NeuroEPO to healthy volunteers: a randomized, parallel, open-label safety study

Abstract Background Delivery of therapeutic agents as erythropoietin (EPO) into Central Nervous System through intranasal route could benefit patients with neurological disorders. A new nasal formulation containing a non-hematopoietic recombinant EPO (NeuroEPO) has shown neuroprotective actions in p...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Orestes Santos-Morales, Alina Díaz-Machado, Daise Jiménez-Rodríguez, Yaisel Pomares-Iturralde, Tatiana Festary-Casanovas, Carlos A. González-Delgado, Sonia Pérez-Rodríguez, Eulalia Alfonso-Muñoz, Carmen Viada-González, Patricia Piedra-Sierra, Idrian García-García, Daniel Amaro-González, for the NeuroEPO Study Group, Julio César García-Rodríguez, Iliana Sosa-Testé, Alicia Lagarto-Parra, Laura Barrero-Viera, Marlene David-Baldo, Maura Tamayo-Rodríguez, Ivonne Rivero-Vázquez, Gricel González-Gamiz, Alis Martín-Trujillo, Yasmila Rodríguez-Fernández, Ana Alfa Ledo-de la Luz, Maylén Álvarez-Delgado, Ivón Howland-Álvarez, Yolanda Cruz-Gómez
Формат: Artigo
Язык:Inglês
Опубликовано: BMC 2017-07-01
Серии:BMC Neurology
Предметы:
Non-hematopoietic recombinant erythropoietin
NeuroEPO
Stroke
Neurodegenerative diseases
Healthy volunteers
Safety
Online-ссылка:http://link.springer.com/article/10.1186/s12883-017-0908-0
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы